<p><strong>Dosage Modification for Adverse Renal Effects</strong>: Interrupt therapy if a progressive increase in SCR (Serum Creatinine Concentration) beyond the ULN occurs. Once SCR returns to within normal limits, reinitiate therapy at a lower dosage followed by gradual dosage escalation if clinical beneht is expected to outweigh potential risks. Reduce dosage by 10 mg/kg daily if SCR at 2 consecutive visits increases to a level &gt;33% above the average pretreatment value and the increase cannot be attributed to other causes.<br />
<br />
<strong>Dosage Modifcation for Adverse Hepatic Effects</strong>: Consider dosage adjustment or interruption of therapy in patients with severe, persistent, progressive, or unexplained elevations of liver function test results.</p>